Money Matters: Financing the Battle Against AMR.

As AMR poses a significant global health threat — projected to cause 10 million deaths and cost health systems up to $100 trillion by 2050 — the world leaders pledged to reduce AMR-associated deaths by 10% by 2030 at a recent UN General Assembly. Sustainable financing for national action plans is crucial.

Despite ongoing efforts, the antibiotic pipeline remains dry, with only 13 new antibiotics approved since 2017. This highly needs innovative financing models. According to The World Economic Forum, public-private partnerships (PPPs) are vital in combating AMR by combining resources and expertise from both sectors. These collaborations aim to create innovative funding mechanisms, enabling pharmaceutical and biotech companies to pursue R&D with reduced financial risk. In addition, hybrid funding approaches, which combine the push incentives (grants and subsidies) and pull subsidies (market entry rewards and subscription models), can ensure sustainable investment in new antibiotics. 

Reference:

Bishen, S. (2024, October 10). Funding the future: Sustainable financing models to help the fight against antimicrobial resistance. World Economic Forum. https://www.weforum.org/agenda/2024/10/sustainable-financing-models-help-fight-against-antimicrobial-resistance/